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S-Adenosylmethionine and 5-Methyltetrahydrofolate Are
Associated With Endothelial Function After Controlling for
Confounding by Homocysteine
The Hoorn Study
A.M.W. Spijkerman, Y.M. Smulders, P.J. Kostense, R.M.A. Henry, A. Becker, T. Teerlink, C. Jakobs,
J.M. Dekker, G. Nijpels, R.J. Heine, L.M. Bouter, C.D.A. Stehouwer
Objective—To explore to what extent homocysteine, S-adenosylmethionine (SAM), S-adenosylhomocysteine, total folate,
5-methyltetrahydrofolate (5-MTHF), vitamin B12, and vitamin B6 are associated with endothelium-dependent,
flow-mediated vasodilation (FMD), and whether these associations are stronger in individuals with diabetes or other
cardiovascular risk factors.
Methods and Results—In this population-based study of 608 elderly people, FMD and endothelium-independent
nitroglycerin-mediated dilation (NMD) were ultrasonically estimated from the brachial artery (absolute change in
diameter [m]). High SAM and low 5-MTHF were significantly associated with high and low FMD, respectively (linear
regression coefficient, [95% confidence interval]): 48.57 m (21.16; 75.98) and 32.15 m (59.09; 5.20), but high
homocysteine was not (15.11 m (42.99; 12.78). High SAM and low 5-MTHF were also significantly associated
with high and low NMD, respectively. NMD explained the association of 5-MTHF with FMD but not of SAM. No
interactions were observed for diabetes or cardiovascular risk factors.
Conclusions—In this elderly population, both SAM and 5-MTHF are associated with endothelial and smooth muscle cell
function. The effect of homocysteine on endothelial function is relatively small compared with SAM and 5-MTHF. The
relative impact of SAM, 5-MTHF, and homocysteine, and the mechanisms through which these moieties may affect
endothelial and smooth muscle cell function need clarification. (Arterioscler Thromb Vasc Biol. 2004;25:778-784.)
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The mechanisms responsible for the association of hyper-homocystinemia with cardiovascular disease1,2 are in-
completely understood. A leading hypothesis is that homo-
cysteine increases oxidative stress and impairs endothelial
function,3 which is a key factor in the pathogenesis of
atherosclerosis.4 Hyperhomocystinemia has been associated
with impaired endothelium-dependent vasodilation,5–7 al-
though this finding is by no means universal.5,8,9
A complementary hypothesis is that the association be-
tween hyperhomocystinemia and endothelial dysfunction
may be partly explained by factors involved in homocysteine
metabolism. Homocysteine is produced from methionine via
S-adenosylmethionine (SAM) and S-adenosylhomocysteine
(SAH) (Figure 1). Homocysteine can be remethylated to
methionine in a reaction that requires folate and vitamin B12,
or it can enter the transsulfuration pathway, which requires
vitamin B610 (Figure 1).
It has been suggested that the association between hyper-
homocystinemia and cardiovascular disease may be ex-
plained by a low SAM or a high SAH concentration or a low
SAM/SAH ratio,11–13 and/or by low concentrations of folate,
vitamin B6, or vitamin B12.14–17 Another additional hypoth-
esis is that hyperhomocystinemia (or related components)
affects vascular function more strongly in the presence of
other cardiovascular risk factors,18,19 particularly type 2
diabetes.20
We explored these latter 2 hypotheses in a large
population-based study. We determined to what extent ho-
mocysteine, SAM and SAH, total folate and 5-MTHF,
vitamin B12 and vitamin B6, were associated with brachial
artery endothelium-dependent flow-mediated vasodilation
(FMD), after controlling for potential confounding. We also
assessed whether the associations of these components of
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homocysteine metabolism with FMD were stronger in indi-
viduals with diabetes and other cardiovascular risk factors, as
compared with those without.
Methods
Study Population
For the present investigation, we used data from the 2000 Hoorn
Study follow-up examination and the Hoorn Screening Study, both
of which were population-based.21,22 The study population (n822)
consisted of 290 individuals with normal glucose metabolism, 187
with impaired glucose metabolism and 345 type 2 diabetic mellitus
patients.23 The local ethics committee approved the study. All
participants gave their written informed consent.
Measurement of Endothelium-Dependent and
Endothelium-Independent Dilation
The ultrasound examination was performed according to the guide-
lines of the International Brachial Artery Reactivity Task Force24 and
has previously been described in detail.21 Please see http://atvb.
ahajournals.org for details. FMD is largely mediated by endotheli-
um-derived nitric oxide and is considered to reflect endothelial
function. Nitroglycerin-mediated dilation (NMD) is considered to
reflect smooth muscle cell function and to be a control test for FMD.
There is evidence that impairment of NMD itself is also associated
with an adverse cardiovascular prognosis.25
Sample Preparation and Determination of
Homocysteine, SAM and SAH, and B Vitamins
All blood sampling and sample processing was previously described
in detail.26,27 Please see online supplement (available at http://
atvb.ahajournals.org) for details.
Measurements of Potential Confounding and/or
Mediating Factors
Health status, medical history, current medication use, and smoking
habits were assessed by a questionnaire.28 We determined systolic
and diastolic pressure, plasma glucose, serum creatinine, serum
albumin, serum urea, lipid profiles, body mass index (BMI), and
waist-to-hip ratio, as described elsewhere.28,29 Hypertension and
previous cardiovascular disease were defined as described previous-
ly,28 and glomerular filtration rate was estimated according to Levey
formula.30
Statistical Analyses
All analyses were performed with SPSS 11.0 for Windows 2000
(SPSS, Chicago, Ill). Please see online supplement for details. In
brief, we used multiple linear regression analysis to study every
single component of homocysteine metabolism in turn as the central
determinant of FMD and/or NMD. None of the associations with
FMD or NMD was linear and this nonlinearity remained after
log-transformation or taking the square root of the independent
variables. Because of this consistent nonlinearity, participants were
divided in groups of equal size according to levels of components of
homocysteine metabolism (tertiles). We compared the highest tertile
to the lower 2 tertiles for components for which high levels are
known to be associated with an adverse cardiovascular risk profile
(for example homocysteine) and vice versa (for example 5-MTHF).
The highest tertile of SAM was compared with the lower 2, because
of our previous observation of a favorable effect of high SAM on
intima-media thickness of the carotid artery.27 In regression models
for FMD, we considered age, sex, glucose tolerance status, baseline
diameter, and the increase in peak systolic velocity as standard
correction variables (Table 2, standard model)31,32. In the models for
NMD, we always included age, sex, glucose tolerance status, and
baseline diameter (Table 2, standard model). Potential confounding
factors were selected through the change in estimate approach.33
P0.05 was considered statistically significant. Interaction was
tested with product terms. Because of the large number of interac-
tions (n56), the level of significance for interaction was set at
P0.01.
Results
The present population consisted of 608 individuals because
214 participants had qualitatively unsatisfactory ultrasound
examinations21 and/or missing data on homocysteine. The
group with missing data had a significantly higher BMI, more
frequently had type 2 diabetes and hypertension, was signif-
icantly older, had higher homocysteine, pyridoxal-5-
phosphate, SAM and SAH levels, a lower glomerular filtra-
tion rate, and less favorable lipid profiles (data not shown).
The analyses with NMD as the dependent variable were
performed in 576 individuals with complete data. We ex-
cluded 2 participants with very high 5-MTHF and pyridoxal-
5-phosphate levels for all analyses concerning 5-MTHF and
pyridoxal-5-phosphate.
Tables 1 and 2 show the clinical characteristics and
brachial artery characteristics of the study population.
Homocysteine Is Inversely but Not Statistically
Significantly Associated With FMD and NMD
Homocysteine in the highest tertile (12.2mmol/L) was
associated with low FMD and low NMD, but not significantly
so (Figure 2A and 2B; Table 3, standard model). The weak
association of homocysteine with FMD was further attenu-
ated by adjustment for 5-MTHF and plasma SAM (Table 3,
model 1). Individual adjustment of the standard model for
plasma SAM/SAH ratio, or total folate or pyridoxal-5-
phosphate produced a similar attenuation (data not shown).
Adjustment for previous cardiovascular disease and smoking
(Table 3, model 3) also further weakened the association of
homocysteine with FMD and NMD. Additional adjustment
for glomerular filtration rate or plasma SAH or vitamin B12
enhanced the association between high homocysteine and low
FMD and low NMD, but the association remained statisti-
cally insignificant (data not shown). Lipid levels, statin use,
BMI, and waist-to-hip ratio did not have any impact on the
association between homocysteine and FMD or NMD, nor
did SAM/SAH ratio in erythrocytes, systolic and diastolic
blood pressure, hypertension, or microalbuminuria (data not
shown). A similar association was observed for homocysteine
15 mol/L and FMD (please see online supplement).
Figure 1. Homocysteine methionine metabolism.
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Plasma SAM and Plasma 5-MTHF Are Directly
Associated With FMD and NMD After Controlling
for Confounding by Homocysteine or
Cardiovascular Risk Factors
Plasma SAM in the highest tertile was associated with higher
FMD and NMD, and 5-MTHF in the lowest tertile was
associated with lower FMD and NMD compared with the
remaining tertiles (Figure 2A and 2B; Table 3, standard
model). The associations of high SAM and low 5-MTHF with
high and low FMD and NMD, respectively, were statistically
significant after controlling for confounding by each other or
by homocysteine (Table 3, models 1 and 2). They were also
statistically significant after controlling for confounding by
cardiovascular risk factors (Table 3, model 3). Adjustment for
plasma SAH, SAM/SAH ratio in plasma or erythrocytes, total
folate, pyridoxal-5-phosphate or B12, lipid levels, BMI, or
waist-to-hip ratio had little impact on the aforementioned
associations (data not shown).
The Association of SAM With FMD Is Significant
After Controlling for Confounding by NMD
The large impact of adjustment for NMD on the associations
of high homocysteine and low 5-MTHF with FMD (Table 3,
model 4) showed that these associations were largely ex-
plained by NMD. In contrast, high SAM in plasma remained
positively and significantly associated with FMD after adjust-
ment for NMD (Table 3, model 4).
The Associations of SAM and 5-MTHF With FMD
Are Stronger Than That of Homocysteine
With FMD0
High SAM was associated with a 48.57-m higher FMD
compared with low SAM and low 5-MTHF with a 32.15-m
TABLE 1. Characteristics of the Study Population
Clinical Characteristics
Homocysteine 12.2
(Lower 2 Tertiles), N402
Homocysteine 12.2
(Highest Tertile), N206
Age, y 66.66.5 69.86.8
Sex, male/female (% male) 219/183 (45.5) 88/118 (57.3)
Body mass index, kg/m2 27.33.7 26.93.4
Systolic blood pressure, mm Hg 14019 14419
Diastolic blood pressure, mm Hg 769 779
Hypertension 140/90 mm Hg, % 65.7 71.4
Use of ACE-inhibitor/calcium antagonist, % 10.2/9.5 14.1/12.6
Current smoker, % 13.8 16.5
Previous cardiovascular disease, % 46.0 48.3
NGM/IGM/DM, n 156/80/162 76/53/74
Total cholesterol, mmol/L 5.81.1 5.61.0
Statin therapy, % 15.2 14.6
Glomerular filtration rate, mL/min* 68.19.9 63.512.6
Homocysteine Metabolism
Homocysteine, mol/L 9.5 (8.3–10.6) 14.1 (13.1–16.2)
SAM-plasma, nmol/L 87.2 (76.6–99.3) 89.9 (78.2–101.0)
SAM-erythrocytes, nmol/L 3627 (3226–4111) 3728 (3233–4096)
SAH-plasma, nmol/L 13.3 (11.3–16.2) 16.6 (13.9–19.8)
SAH-erythrocytes, nmol/L 136 (114–164) 140 (109–171)
SAM/SAH-ratio plasma 6.4 (5.6–7.4) 5.5 (4.6–6.3)
SAM/SAH-ratio erythrocytes 26.1 (21.4–33.7) 26.9 (20.6–34.0)
Folate-serum, nmol/L 16.8 (13.3–21.4) 12.6 (10.1–15.9)
Folate-erythrocytes, nmol/L 615 (500–742) 500 (404–642)
Folate deficiency, %, 5.9 nmol/L — 2.5
5-MTHF, nmol/L 12.2 (9.1–17.1) 8.4 (6.4–10.8)
Vitamin B12, pmol/L 294 (242–362) 246 (202–306)
B12 deficiency, %, 150 pmol/L 1.5 3.0
Pyridoxal-5-phosphate, nmol/L 40 (28–57) 31 (23–42)
Pyridoxal-5-phosphate deficiency, %, 20 nmol/L 6.8 16.5
Data are presented as meanSD, number (percentage), or median (interquartile range).
ACE indicates angiotensin-converting enzyme; DM type 2 diabetes mellitus; IGM, impaired glucose metabolism;
NGM, normal glucose metabolism, SAM, S-adenosyl-methionine; SAH, S-adenosyl-homocysteine; 5-MTHF,
5-methyltetrahydrofolate.
*Glomerular filtration rate was estimated by Levey equation and expressed per 1.73m2.
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lower FMD compared with high 5-MTHF, which reflected
stronger associations than the 15.11-m lower FMD associ-
ated with high homocysteine compared with low homocys-
teine. For comparison, in a previous analysis in the same
cohort, diabetes was associated with a 60-m lower FMD
compared with people without diabetes,21 and smoking,
hypertension, and previous cardiovascular disease were asso-
ciated with a 65.1-m, 26.1-m, and 36.6-m lower FMD,
compared with nonsmokers, and to individuals without hy-
pertension or previous cardiovascular disease, respectively
(Figure I, available online at http://atvb.ahajournals.org).
The Remaining Components of Homocysteine
Metabolism Are Not Significantly Associated With
FMD or NMD0
The associations of SAM in erythrocytes, SAH in plasma and
erythrocytes, SAM/SAH ratio in plasma and erythrocytes,
folate in serum and erythrocytes, vitamin B12, and pyridoxal-
5-phosphate with FMD and NMD were not statistically
significant, and these associations were further attenuated by
adjustment for 5-MTHF, SAM plasma, homocysteine or
pyridoxal-5-phosphate, and for previous cardiovascular dis-
ease, smoking, diastolic blood pressure, and glomerular
filtration rate, or for NMD (data not shown).
The Associations Between Components of
Homocysteine Metabolism and FMD and
NMD Are not Stronger in the Presence of
Cardiovascular Risk Factors Than in
Their Absence
The association of all components of homocysteine metab-
olism with FMD and NMD did not differ over glucose
tolerance categories, for example, P interaction (homocys-
teine  glucose tolerance) for FMD: 0.902 in impaired
glucose metabolism and 0.260 in diabetic mellitus, respec-
tively, and P interaction (homocysteine  glucose tolerance)
for NMD: 0.678 in impaired glucose metabolism and 0.579 in
diabetic mellitus, respectively. In addition, no interactions
were observed for age, sex, hypertension, smoking, previous
cardiovascular disease, and hypercholesterolemia (P interac-
tion 0.01) (data not shown).
Discussion
The most important findings of this study are: (1) high SAM
plasma levels were associated with high FMD and NMD; (2)
low 5-MTHF levels were associated with low FMD and
NMD; (3) homocysteine was inversely but not significantly
associated with FMD and NMD; (4) NMD largely explained
the associations of 5-MTHF and homocysteine (but not
SAM) with FMD; and (5) the associations between compo-
nents of homocysteine metabolism and FMD and NMD were
not stronger in the presence of cardiovascular risk factors
than in their absence. Taken together, our findings support the
concept that components of homocysteine metabolism, such
as SAM and 5-MTHF, may affect vascular function. In
contrast, our results argue against the notions that the asso-
ciation between homocysteine and vascular function can be
explained by other components of homocysteine metabolism
or by interactions with other cardiovascular risk factors.
Our study is the first to observe a direct association of high
levels of SAM with FMD and NMD after controlling for
confounding by homocysteine and other cardiovascular risk
factors. Taken together with our previous finding of lower
carotid intima-media thickness in nondiabetic individuals
with high SAM levels,27 these data suggest that SAM may
have beneficial effects on the vessel wall, possibly by
increasing methyl group availability, which is crucial to the
biosynthesis and stability of proteins, RNA, and DNA.34,35
SAH is a potent inhibitor of SAM-dependent transmethyla-
TABLE 2. Brachial Artery Characteristics of the
Study Population
Right Brachial Artery
Characteristics
Homocysteine
12.2, N402
Homocysteine
12.2, N206
Diameter, m
Baseline 4602746 4771735
After FMD 4782746 4921721
After NMD 5065739 5155739
Absolute change in diameter, m
After FMD 180170 150164
After NMD 464241 409216
FMD/NMD ratio, % 4031 3357
Peak systolic velocity, cm/s
Baseline 5813 5914
After reactive hyperemia 10626 10627
Data are presented as meanSD.
FMD indicates flow-mediated vasodilation; NMD, nitroglycerin-mediated
vasodilation.
Figure 2. Mean absolute change in diameter (m) for flow-
mediation dilation (A) and nitroglycerine-mediated dilation (B) for
tertiles of homocysteine, plasma SAM, and 5-MTHF, adjusted
for age, sex, glucose tolerance status, baseline diameter, and,
for FMD, increase in peak systolic velocity. Tertile ranges homo-
cysteine: 5.0 to 9.4; 9.5 to 12.2; 12.3 to 38.5 mol/L. Tertile
ranges SAM-plasma: 25.5 to 80.4; 80.5 to 95.0; 95.2 to 193.4
nmol/L. Tertile ranges 5-MTHF: 1.7 to 8.8; 8.59 to 13.4; 13.5 to
79.7 nmol/L.
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tion reactions.34 Thus, low levels of SAM or high levels of
SAH relative to SAM may result in hypomethylation,34,35
which may lead to impaired endothelial cell regeneration,
endothelial dysfunction,36 and atherosclerosis. To what extent
hypomethylation (of DNA) may explain the association be-
tween SAM and endothelial and smooth muscle cell function
as observed in the present study remains to be established.
Low levels of 5-MTHF, the active form of folate, were
associated with low FMD and low NMD in our study after
controlling for confounding by homocysteine, suggesting a
direct effect of 5-MTHF on endothelial and/or vascular
smooth muscle cells. This finding might be explained by the
fact that in vitro, 5-MTHF has antioxidant properties,37,38
directly interacts with endothelial nitric oxide synthase,37 or
has positive effects on tetrahydrobiopterin (BH4), the essen-
tial cofactor of endothelial nitric oxide synthase.38,39 A direct
effect of 5-MTHF or folic acid on endothelial function, after
controlling for confounding by homocysteine, has also been
observed in patients with familial hypercholesterolemia or
type 2 diabetes without hyperhomocystinemia40,41 and in
hyperhomocystinemia patients with coronary artery
disease.42,43
FMD was 49 m greater in individuals with high SAM
compared with individuals with low SAM, which is similar in
effect size to the inverse association of diabetes with FMD
(60 m).21 FMD was 32 m smaller in individuals with
low 5-MTHF compared with individuals with high 5-MTHF,
which is comparable to the inverse association of previous
cardiovascular disease with FMD (37 m) (Figure I). Thus,
the associations of SAM and 5-MTHF with FMD appear to
be substantial.
Although we cannot exclude an association of homocys-
teine with FMD, our data suggest that in a general elderly
population with a considerable amount of cardiovascular risk
factors, any such association is relatively small (15 m).
In addition, the association of homocysteine with FMD
appeared to be explained by NMD. Impairment of either
endothelial or vascular smooth muscle cell function will
result in impaired FMD; when both FMD and NMD are
impaired, dysfunction of the endothelium cannot be separated
from that of vascular smooth muscle44 and an unequivocal
interpretation of the FMD result is not possible. There is in
vitro evidence that homocysteine can induce smooth muscle
cell proliferation,45,46 which might affect smooth muscle cell
function, and that folic acid can reverse some of these
effects.45 Impaired smooth muscle cell function has been
associated with an adverse cardiovascular prognosis,25 and
our findings of impaired NMD in individuals with high
homocysteine or low SAM and 5-MTHF may be relevant in
this regard. Taken together, these findings stress the need to
TABLE 3. Homocysteine, SAM, and 5-MTHF as Determinants of Flow-Mediated Vasodilation
and Nitroglycerin-Mediated Vasodilation: Multiple Linear Regression Analyses
Central Determinant Dependent: FMD, m Dependent: NMD, m
Homocysteine (highest tertile vs rest)
Standard model 15.11 (42.99; 12.78) 31.41 (71.67; 8.85)
Model 1: standard	low 5-MTHF	high SAM-p 6.43 (35.75; 22.90) 14.23 (58.57; 30.11)
Model 2: standard	homocysteine — —
Model 3: standard	smoking	 prior CVD 8.86 (36.20; 18.55) 26.35 (66.72; 14.02)
Model 4: standard	NMD 0.769 (25.61; 24.07) —
SAM-plasma (highest tertile vs rest)
Standard model 48.57 (21.16; 75.98)* 50.05 (10.06; 90.03)*
Model 1: standard	low 5-MTHF 34.70 (7.45; 61.96)* 45.74 (4.20; 87.29)*
Model 2: standard	homocysteine 41.41 (14.81; 68.01)* 46.76 (6.93; 86.60)*
Model 3: standard	smoking	 prior CVD 50.73 (23.64; 77.82)* 47.34 (6.92; 87.75)*
Model 4: standard	NMD 33.89 (9.24; 58.54)* —
5-MTHF (lowest tertile vs rest)
Standard model 32.15 (59.09;5.20)* 52.64 (93.57;11.70)*
Model 1: standard	high SAM-p 31.10 (58.16;4.03)* 52.45 (93.59;11.31)*
Model 2: standard	homocysteine 29.07 (57.46;0.69)* 45.45 (88.44;2.47)*
Model 3: standard	smoking	 prior CVD 28.33 (55.32;1.34)* 55.15 (96.88;13.43)*
Model 4: standard	NMD 10.60 (34.50; 13.29) —
Data are presented as linear regression coefficients (95% confidence intervals).
High homocysteine, high SAM, and low 5-MTHF are in turn the central determinant (X) in the regression analysis
and either FMD or NMD is the outcome of interest (Y). The coefficient of 15.11 for high homocysteine means that
participants with a homocysteine level above 12.2 mol/l have a 15.11-m lower FMD compared to people with
homocysteine levels below 12.2 mol/L.
*Significant association (P0.05).
Standard model: determinant under consideration	age, sex, glucose tolerance status, baseline diameter, and peak
systolic velocity increase (the latter not included in models for NMD). High SAM-p is highest tertile of plasma SAM.
Highest tertiles: Hcy 12.2 mol/L, SAM-P95.0 nmol/L, and lowest tertile 5-MTHF 8.8 nmol/L.
782 Arterioscler Thromb Vasc Biol. April 2005
elucidate the involvement of vascular smooth muscle cells in
vascular disease related to components of homocysteine
metabolism.
Homocysteine has been found to be a stronger risk factor
for cardiovascular events and mortality in the presence of
type 2 diabetes.20,47 However, in the present study, we
observed no interactions between homocysteine and glucose
metabolism in its relationship with FMD or NMD. Because
diabetic individuals with missing ultrasound data had higher
homocysteine levels than diabetic patients with complete
data, the power to detect such interactions may have been too
small. In addition, increased (selective) mortality among
participants with diabetes and relatively severe hyperhomo-
cystinemia20 may have resulted in a “healthy survivor effect,”
which precluded the observation of an interaction between
homocysteine, glucose tolerance status, and FMD in the
present study.
Our study had some limitations. First, the population
consisted of white individuals in the age range of 50 to 85
with a considerable prevalence of cardiovascular risk factors
and we do not know whether our results can be generalized to
healthier people of the same age or to people from different
age groups or from other ethnic groups. However, as homo-
cysteine concentration increases with age and low to low–
normal concentrations or deficiencies of folate, vitamin B12
and pyridoxal-5-phosphate are relatively common in this age
group, we were able to study the association with FMD and
NMD over a wide range of concentrations. Second, the study
had a cross-sectional design and the observed associations
cannot be interpreted as causal relationships. Third, partici-
pants who were excluded because of missing or unsatisfac-
tory ultrasound data were older, had higher BMI, higher
homocysteine levels, and more frequently had diabetes,
which may have resulted in an underestimation of the
observed associations. Fourth, there was a discrepancy be-
tween the serum levels of total folate (measured by chemilu-
minescence) levels and of 5-MTHF (measured by high-per-
formance liquid chromatography) in our study. However,
total folate and 5-MTHF were inversely and significantly
correlated with homocysteine. The discrepancy may be partly
explained by the fact that not all (81% to 93%) of total serum
folate is methylfolate.48 In addition, laboratory assays of
folate are notoriously difficult and various methods have
previously been known to agree poorly.49,50 We focused on
5-MTHF levels because this folate subform is involved in the
methylation cycle, which includes both SAM and homocys-
teine as metabolic components. Fifth, the assumptions under-
lying the FMD test, such as the concept that nitroglycerin
adequately mimics the effect of endogenous nitric oxide
release,44 still need to established. Nevertheless, there is
increasing evidence that both impaired FMD and impaired
NMD are associated with an adverse cardiovascular progno-
sis25,51 and the FMD test is considered as a reasonable
surrogate measure of cardiovascular risk.52
In conclusion, this study suggests that in this elderly
population, both SAM and 5-MTHF are associated with
endothelial and smooth muscle cell function. In addition, our
study suggests that the effect of homocysteine on endothelial
function may be relatively small compared with SAM,
5-MTHF, or diabetes. Further studies are needed to ascertain
the relative impact of SAM, 5-MTHF, and homocysteine, and
to elucidate the mechanisms through which these moieties
may affect the function of endothelial and vascular smooth
muscle cells.
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